EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
EPHA2 | EPH receptor A2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enhanced |
EPOR | Erythropoietin receptor | Cancer-related genes Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Mixed |
ERBB2 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
ERBB4 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
FADS1 | Fatty acid desaturase 1 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FADS2 | Fatty acid desaturase 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FCER1A | Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide | FDA approved drug targets Predicted membrane proteins
| | | | | Mixed |
FCER1G | Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide | FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
FCGR1A | Fc fragment of IgG, high affinity Ia, receptor (CD64) | CD markers FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
FCGR1B | Fc fragment of IgG, high affinity Ib, receptor (CD64) | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
FCGR2A | Fc fragment of IgG, low affinity IIa, receptor (CD32) | CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
FCGR2B | Fc fragment of IgG, low affinity IIb, receptor (CD32) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
FCGR3A | Fc fragment of IgG, low affinity IIIa, receptor (CD16a) | CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
FCGR3B | Fc fragment of IgG, low affinity IIIb, receptor (CD16b) | CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
FFAR1 | Free fatty acid receptor 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
FGFR1 | Fibroblast growth factor receptor 1 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Expressed in all |
FGFR2 | Fibroblast growth factor receptor 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FKBP1A | FK506 binding protein 1A, 12kDa | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FLT1 | Fms-related tyrosine kinase 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enriched |
FLT3 | Fms-related tyrosine kinase 3 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
FLT4 | Fms-related tyrosine kinase 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FOLH1 | Folate hydrolase (prostate-specific membrane antigen) 1 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
FSHR | Follicle stimulating hormone receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Group enriched |
FXYD2 | FXYD domain containing ion transport regulator 2 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
GABBR1 | Gamma-aminobutyric acid (GABA) B receptor, 1 | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
GABBR2 | Gamma-aminobutyric acid (GABA) B receptor, 2 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enriched |
GABRA1 | Gamma-aminobutyric acid (GABA) A receptor, alpha 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
GABRA2 | Gamma-aminobutyric acid (GABA) A receptor, alpha 2 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Tissue enriched |
GABRA3 | Gamma-aminobutyric acid (GABA) A receptor, alpha 3 | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
GABRA4 | Gamma-aminobutyric acid (GABA) A receptor, alpha 4 | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
GABRA5 | Gamma-aminobutyric acid (GABA) A receptor, alpha 5 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
GABRA6 | Gamma-aminobutyric acid (GABA) A receptor, alpha 6 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Not detected |
GABRB1 | Gamma-aminobutyric acid (GABA) A receptor, beta 1 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
GABRB2 | Gamma-aminobutyric acid (GABA) A receptor, beta 2 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
GABRB3 | Gamma-aminobutyric acid (GABA) A receptor, beta 3 | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
GABRD | Gamma-aminobutyric acid (GABA) A receptor, delta | Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
GABRE | Gamma-aminobutyric acid (GABA) A receptor, epsilon | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
GABRG1 | Gamma-aminobutyric acid (GABA) A receptor, gamma 1 | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
GABRG2 | Gamma-aminobutyric acid (GABA) A receptor, gamma 2 | Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
GABRG3 | Gamma-aminobutyric acid (GABA) A receptor, gamma 3 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
GABRP | Gamma-aminobutyric acid (GABA) A receptor, pi | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
GABRQ | Gamma-aminobutyric acid (GABA) A receptor, theta | FDA approved drug targets Predicted membrane proteins
| | | | | Group enriched |
GABRR1 | Gamma-aminobutyric acid (GABA) A receptor, rho 1 | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
GABRR2 | Gamma-aminobutyric acid (GABA) A receptor, rho 2 | FDA approved drug targets Predicted membrane proteins
| | | | | Not detected |
GABRR3 | Gamma-aminobutyric acid (GABA) A receptor, rho 3 (gene/pseudogene) | FDA approved drug targets Predicted membrane proteins
| | | | | Not detected |
GALNT8 | Polypeptide N-acetylgalactosaminyltransferase 8 | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
GCGR | Glucagon receptor | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
GGCX | Gamma-glutamyl carboxylase | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
GHR | Growth hormone receptor | Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Group enriched |